Background: Renal ischemia-reperfusion injury (IRI) usually causes acute kidney injury. There is an urgent need to develop an effective agent to prevent renal IRI. This study aimed to examine the effect of butyrate on renal IRI in rats. Materials and Methods: Rats were randomly assigned into 3 groups (10 rats in each group): the sham group, the IRI group, and the butyrate group. Rats were injected intravenously with 300 mg/kg of sodium butyrate in the butyrate group and with a saline solution in the sham group and IRI group 30 min before renal ischemia. After 24 h of reperfusion, renal function and histologic damage were examined. Myeloperoxidase (MPO) activity assay, in situ apoptosis examination, enzyme-linked immunosorbent assay, immunohistochemical assay, and Western blot were performed as well. Results: Butyrate pretreatment significantly reduced renal dysfunction and histologic damage induced by renal IRI. Butyrate pretreatment caused a significant attenuation of neutrophil infiltration, which was reflected by the reduction of renal MPO activity. Butyrate also reduced apoptotic tubular cell death and improved caspase-3 activation. The expression of TNF-α was decreased following butyrate pretreatment. Conclusions: Butyrate pretreatment protects rats from renal IRI by inhibiting inflammation and apoptosis. Therefore, butyrate may be a potential therapeutic agent for preventing renal IRI.

Keywords:
Kidney, Ischemia-reperfusion injury, Inflammation, Apoptosis
1.
Thadhani R, Pascual M, Bonventre JV. Acute renal failure.
N Engl J Med
. 1996 May; 334(22): 1448–60.
2.
Devarajan P. Update on mechanisms of ischemic acute kidney injury.
J Am Soc Nephrol
. 2006 Jun; 17(6): 1503–20.
3.
Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury.
J Clin Invest
. 2011 Nov; 121(11): 4210–21.
4.
Bellomo R, Kellum JA, Ronco C. Acute kidney injury.
Lancet
. 2012 Aug; 380(9843): 756–66.
5.
Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al.; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study.
JAMA
. 2005 Aug; 294(7): 813–8.
6.
Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, et al. Every minute counts when the renal hilum is clamped during partial nephrectomy.
Eur Urol
. 2010 Sep; 58(3): 340–5.
7.
Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy.
J Clin Invest
. 2004 Jul; 114(1): 5–14.
8.
Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
Nat Rev Drug Discov
. 2002 Apr; 1(4): 287–99.
9.
Zhang LT, Yao YM, Lu JQ, Yan XJ, Yu Y, Sheng ZY. Sodium butyrate prevents lethality of severe sepsis in rats.
Shock
. 2007 Jun; 27(6): 672–7.
10.
Meijer K, de Vos P, Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health?
Curr Opin Clin Nutr Metab Care
. 2010 Nov; 13(6): 715–21.
11.
Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation.
J Nutr
. 2002 May; 132(5): 1012–7.
12.
Liu T, Li J, Liu Y, Xiao N, Suo H, Xie K, et al. Short-chain fatty acids suppress lipopolysaccharide-induced production of nitric oxide and proinflammatory cytokines through inhibition of NF-κB pathway in RAW264.7 cells.
Inflammation
. 2012 Oct; 35(5): 1676–84.
13.
Liu B, Qian J, Wang Q, Wang F, Ma Z, Qiao Y. Butyrate protects rat liver against total hepatic ischemia reperfusion injury with bowel congestion.
PLoS One
. 2014 Aug; 9(8):e106184.
14.
Sun J, Wang F, Li H, Zhang H, Jin J, Chen W, et al. Neuroprotective Effect of Sodium Butyrate against Cerebral Ischemia/Reperfusion Injury in Mice.
BioMed Res Int
. 2015; 2015: 395895.
15.
Liu B, Ma ZY, Wu G, Qian JM. Butyrate protects rats from hepatic ischemia/reperfusion injury.
Int J Clin Exp Med
. 2015 Apr; 8(4): 5406–13.
16.
Qiao YL, Qian JM, Wang FR, Ma ZY, Wang QW. Butyrate protects liver against ischemia reperfusion injury by inhibiting nuclear factor kappa B activation in Kupffer cells.
J Surg Res
. 2014 Apr; 187(2): 653–9.
17.
Weight SC, Furness PN, Nicholson ML. New model of renal warm ischaemia-reperfusion injury for comparative functional, morphological and pathophysiological studies.
Br J Surg
. 1998 Dec; 85(12): 1669–73.
18.
Ma D, Lim T, Xu J, Tang H, Wan Y, Zhao H, et al. Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation.
J Am Soc Nephrol
. 2009 Apr; 20(4): 713–20.
19.
Letavernier E, Perez J, Joye E, Bellocq A, Fouqueray B, Haymann JP, et al. Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure.
J Am Soc Nephrol
. 2005 Aug; 16(8): 2395–402.
20.
Zheng Y, Lu M, Ma L, Zhang S, Qiu M, Ma X. Osthole ameliorates renal ischemia-reperfusion injury by inhibiting inflammatory response.
Urol Int
. 2013; 91(3): 350–6.
21.
Jang HS, Kim J, Park YK, Park KM. Infiltrated macrophages contribute to recovery after ischemic injury but not to ischemic preconditioning in kidneys.
Transplantation
. 2008 Feb; 85(3): 447–55.
22.
Yang B, Jain S, Ashra SY, Furness PN, Nicholson ML. Apoptosis and caspase-3 in long-term renal ischemia/reperfusion injury in rats and divergent effects of immunosuppressants.
Transplantation
. 2006 May; 81(10): 1442–50.
23.
Daemen MA, van ’t Veer C, Denecker G, Heemskerk VH, Wolfs TG, Clauss M, et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation.
J Clin Invest
. 1999 Sep; 104(5): 541–9.
24.
Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice.
FASEB J
. 2008 Oct; 22(10): 3549–60.
25.
Hu X, Zhang K, Xu C, Chen Z, Jiang H. Anti-inflammatory effect of sodium butyrate preconditioning during myocardial ischemia/reperfusion.
Exp Ther Med
. 2014 Jul; 8(1): 229–32.
26.
Andreucci M, Faga T, Pisani A, Sabbatini M, Michael A. Acute kidney injury by radiographic contrast media: pathogenesis and prevention.
BioMed Res Int
. 2014; 2014: 362725.
27.
Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury.
Nat Rev Nephrol
. 2011 Apr; 7(4): 189–200.
28.
Kanagasundaram NS. Pathophysiology of ischaemic acute kidney injury.
Ann Clin Biochem
. 2015 Mar; 52(Pt 2): 193–205.
29.
Kusch A, Hoff U, Bubalo G, Zhu Y, Fechner M, Schmidt-Ullrich R, et al. Novel signalling mechanisms and targets in renal ischaemia and reperfusion injury.
Acta Physiol (Oxf)
. 2013 May; 208(1): 25–40.
30.
Ashkenazi A, Dixit VM. Death receptors: signaling and modulation.
Science
. 1998 Aug; 281(5381): 1305–8.
31.
Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand.
J Clin Invest
. 1997 Jun; 99(11): 2682–90.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.